Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis

NCT07067463 is registered in ClinicalTrials.gov with Zenas BioPharma (USA), LLC as lead sponsor.

NCT NCT07067463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07067463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Lead sponsor
Zenas BioPharma (USA), LLC
Phase
Phase 3
Overall status
Recruiting
Start date
March 23, 2026
Completion date
July 31, 2030
Enrollment
705 (estimated)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis (ms) primary progressive